Navigation Links
Transcept Pharmaceuticals Appoints Key Senior Executives
Date:7/2/2008

cutives with extensive experience in both pharmaceutical development and commercialization," said Ms. Koppy. "I look forward to leading the Transcept effort to build partner relationships and to license development programs."

About Intermezzo(R)

Transcept Pharmaceuticals' lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the company's proprietary Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. This novel pH modification delivery system has been shown to accelerate the bioavailability of zolpidem, despite the substantially lower Intermezzo(R) dose vs. the doses employed with previously available forms of this active agent.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the Company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... August 26, 2015 Israel Proves Its Place ... 1 st place  Wayerz comes in 5 th ... Israel by venture capital fund JVP, with Chinese consulting ... China , Israel , ... Impressive achievement for the Israeli representatives in the final ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... PRC ... to develop new business relationships with local sponsors in southern California. The Clinical Trial ... their drug development processes and regulatory pathways., , Stem ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Calif., May 12 USGI Medical, Inc. (USGI),the ... company has,licensed its incisionless surgery technology to Intuitive ... Financial terms of the deal,were not disclosed., ... development,including their intellectual property," said Gary Guthart, president ...
... N.J., May 12 Synvista Therapeutics,Inc. (Amex: ... with the,appointment of David C. Tantillo as Senior ... today, Mr. Tantillo will be responsible,for planning and ... expects commercial launch of this,product in mid- 2009., ...
... PARSIPPANY, N.J., May 12 Forest,Laboratories, Inc. ... company, and,Daiichi Sankyo, Inc. today announced that ... (amlodipine and olmesartan medoxomil),Daiichi Sankyo,s fixed-dose combination ... besylate and the angiotensin receptor,blocker olmesartan medoxomil. ...
Cached Biology Technology:USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 2USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 3Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 2Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 3Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 4Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... An international consortium of researchers led by Universitat ... patients and studies the clinical impact of the mutations. ... the origins and world distribution of some of the ... in Europe thousands of years ago and later migrated ...
... by Innsbruck University Botanic Garden, with support from ... a practical, one-year, continual professional development (CPD) course ... countries. Its focus on inquiry-based science education (IBSE) ... that IBSE methods are more effective than current ...
... biofuels produced from crop biomass as an environmentally ... questions whether the potential climate benefit of sugarcane ... management are considered. Scientists examined the ... greenhouse gas emissions. They found that land use ...
Cached Biology News:New advances in genetic studies of Fanconi anemia patients 2Hands-on learning turns children's minds on to science 2
... Tissue Arrays contain 60 rabbit tissue samples arrayed ... 4 unstained slides and 1 hematoxylin and eosin ... contains 15 different tissues from 4 rabbit organisms, ... slide. Each tissue sample (or core) is 1.5 ...
... offers custom peptide synthesis with a wide variety ... fit your research needs. Purity: ... 2mg-1g Sequence Length: Up ... Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA ...
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... our corresponding peptide and ... 5 I-labelled peptide, ... (H-1470) and ([ 1 ...
... enables you to identify over 150 ... distinguish protein isoforms, protein subsets, and ... visualize peptide-protein associations and relationships easily. ... identification and relative protein expression analysis ...
Biology Products: